ClinicalTrials.gg
CompletedNCT00806026RLSUpdated Jan 26, 2021Results posted

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients

A Phase 3 interventional study of placebo and pregabalin and pramipexol in Idiopathic Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 110 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
731
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.

Enrollment
5th of 95
731 · median 46
Started
2008
with 5 others
Phase 3
18 of 107
none open now
Registered
33rd of 107
by date
Lead sponsor
3 of 107
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 5th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2008, is one of 18 in phase 3, and was the 33rd registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Restless Legs Syndrome with a site in United States, or all of them as a file.
02

Study summary

This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.

03

Conditions studied

  • Idiopathic Restless Legs Syndrome

Keywords

  • RLS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • idiopathic RLS with the presence of all four clinical manifestations of RLS
  • RLS symptoms occur predominantly in the evening
  • RLS history at least 6 months
  • IRLS => 15 at the beginning and the end of placebo run-in
  • Have =>15 nights with RLS symptoms in the month prior to screening

Exclusion criteria

Exclusion Criteria:

  • Any secondary RLS
  • Current augmentation due to RLS treatment
  • Placebo responders identified during the placebo run-in
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
731 participants (actual)

Study arms

  • Experimental
    PBO/PGB 300 mg

    Drug: placebo and pregabalin

  • Active comparator
    PBO/PPX 0.25 mg

    Drug: pramipexol

  • Active comparator
    PBO/PPX 0.5 mg

    Drug: pramipexol

  • Experimental
    PGB 300 mg

    Drug: Pregabalin

  • Active comparator
    PPX 0.25 mg

    Drug: pramipexol

  • Active comparator
    PPX 0.5 mg

    Drug: pramipexol

Interventions

  • Drugplacebo and pregabalin

    following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.

    Also known as: Lyrica

  • following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

    Also known as: Mirapex

  • following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.

    Also known as: Mirapex

  • pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

    Also known as: Lyrica

  • pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

    Also known as: Mirapex

  • pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months

    Also known as: Mirapex

06

What researchers measure

Primary outcomes

  1. Restless Legs Syndrome (RLS) Symptom Severity

    International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

    Time frame: Baseline

  2. Change From Baseline in the RLS Symptom Severity at Week 12

    IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

    Time frame: Baseline, Week 12

  3. Percentage of Participants Responding to Treatment at Week 12

    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".

    Time frame: Week 12

  4. Percentage of Participants With Augmentation

    Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

    Time frame: Baseline

  2. Change From Baseline in SSQ: Subjective WASO at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

    Time frame: Baseline, Week 12

  3. Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.

    Time frame: Week 12

  4. Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.

    Time frame: Week 12

  5. Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.

    Time frame: Week 12

  6. Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12

    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.

    Time frame: Week 12

  7. RLS-Next Day Impact (RLS-NDI)

    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

    Time frame: Baseline

  8. Change From Baseline in RLS-NDI at Week 12

    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

    Time frame: Baseline, Week 12

  9. Limb Pain-Visual Analog Scale (Limb Pain-VAS)

    100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

    Time frame: Baseline

  10. Change From Baseline in Limb Pain-VAS at Week 12

    100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.

    Time frame: Baseline, Week 12

  11. Severity of Augmentation Symptoms at Week 12

    ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

    Time frame: Week 12

  12. Clinical Global Impressions-Severity (CGI-S) at Week 12

    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.

    Time frame: Week 12

  13. Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12

    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.

    Time frame: Week 12

  14. Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12

    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.

    Time frame: Week 12

  15. Profile of Mood State (POMS) at Week 12

    POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.

    Time frame: Week 12

  16. Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12

    RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.

    Time frame: Week 12

  17. Medical Outcomes Study-Short Form 36 (SF-36) at Week 12

    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.

    Time frame: Week 12

  18. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12

    WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.

    Time frame: Week 12

07

Results

Posted Sep 27, 2012
Limitations and caveats
Names of Daytime Function-Participant Reported Outcome (DF-PRO) and Limb Pain-Numerical Rating Scale (Limb Pain-NRS) were updated to RLS-NDI and Limb Pain-VAS respectively to reflect measurement appropriately.

Participant flow

Participant flow — Overall Study
MilestonePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo to Pregabalin 300 mgPlacebo to Pramipexole 0.25 mgPlacebo to Pramipexole 0.5 mg
Started185183182615961
Treated182178180595961
Completed938289322929
Not completed9210193293032
Withdrew: Death000100
Withdrew: Did not meet entrance criteria412100
Withdrew: Lack of efficacy51813487
Withdrew: Lost to follow-up8158266
Withdrew: Withdrawal by subject14179253
Withdrew: Other368204
Withdrew: Protocol violation699023
Withdrew: Adverse event5235441799

Outcome measures

PrimaryRestless Legs Syndrome (RLS) Symptom Severity

International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

Time frame:
Baseline
Reported as:
Mean · Units on a Scale
Restless Legs Syndrome (RLS) Symptom Severity
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Restless Legs Syndrome (RLS) Symptom Severity22.30 ± 5.7322.40 ± 5.3722.10 ± 5.1922.40 ± 5.58
PrimaryChange From Baseline in the RLS Symptom Severity at Week 12

IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in the RLS Symptom Severity at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Change From Baseline in the RLS Symptom Severity at Week 12-11.80 ± 0.47-7.90 ± 0.49-10.50 ± 0.47-7.30 ± 0.48
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (This analysis was step 1 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Least squares (ls) mean difference: -4.50 · 95% CI -5.90 to -3.20Spatial power covariance structure was used.
  • Pramipexole 0.25 mg vs Placebo · Mixed Models Analysis · p = 0.3603 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -0.6 · 95% CI -2.0 to 0.7Spatial power covariance structure was used.
  • Pramipexole 0.5 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -3.2 · 95% CI -4.5 to -1.9Spatial power covariance structure was used.
PrimaryPercentage of Participants Responding to Treatment at Week 12

CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Responding to Treatment at Week 12
Percentage of participantsPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Percentage of Participants Responding to Treatment at Week 1271.4051.2062.7046.80
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (This analysis was step 2 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.)
  • Pramipexole 0.25 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4393 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.)
  • Pramipexole 0.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0022 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.)
PrimaryPercentage of Participants With Augmentation

Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

Time frame:
Baseline up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Augmentation
Percentage of participantsPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mg
Percentage of Participants With Augmentation1.706.609.00
Statistical analysis
  • Pregabalin 300 mg vs Pramipexole 0.25 mg · Log Rank · p = 0.0826 (This analysis was step 6 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.)
  • Pregabalin 300 mg vs Pramipexole 0.5 mg · Log Rank · p = 0.0012 (This analysis was step 3 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.)
SecondarySubjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

Time frame:
Baseline
Reported as:
Mean · minutes
Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)
minutesPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)90.60 ± 76.10100.20 ± 85.9283.90 ± 77.3579.50 ± 69.85
SecondaryChange From Baseline in SSQ: Subjective WASO at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · minutes
Change From Baseline in SSQ: Subjective WASO at Week 12
minutesPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Change From Baseline in SSQ: Subjective WASO at Week 12-49.86 ± 3.06-33.69 ± 3.15-37.18 ± 3.04-32.61 ± 3.10
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Mixed Models Analysis · p = <0.0001 (This analysis was step 7 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -17.25 · 95% CI -25.76 to -8.74Spatial power covariance structure was used.
  • Pramipexole 0.25 mg vs Placebo · Mixed Models Analysis · p = 0.8075 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -1.07 · 95% CI -9.73 to 7.58Spatial power covariance structure was used.
  • Pramipexole 0.5 mg vs Placebo · Mixed Models Analysis · p = 0.2906 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -4.57 · 95% CI -13.05 to 3.91Spatial power covariance structure was used.
SecondarySubjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.

Time frame:
Week 12
Reported as:
Mean · minutes
Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12
minutesPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 1241.60 ± 35.7643.10 ± 35.8435.90 ± 33.0847.70 ± 44.89
SecondarySubjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.

Time frame:
Week 12
Reported as:
Mean · hours
Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12
hoursPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 127.00 ± 1.056.70 ± 1.196.80 ± 1.096.70 ± 1.16
SecondarySubjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.

Time frame:
Week 12
Reported as:
Mean · awakenings
Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12
awakeningsPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 121.10 ± 1.141.70 ± 1.221.50 ± 1.081.80 ± 2.14
SecondarySubjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12

SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12
Units on a scalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 1266.50 ± 20.0057.40 ± 19.8360.20 ± 19.4357.70 ± 20.27
SecondaryRLS-Next Day Impact (RLS-NDI)

The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

Time frame:
Baseline
Reported as:
Mean · Units on a Scale
RLS-Next Day Impact (RLS-NDI)
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
RLS-Next Day Impact (RLS-NDI)49.30 ± 22.0351.90 ± 18.6258.40 ± 20.2750.00 ± 22.64
SecondaryChange From Baseline in RLS-NDI at Week 12

The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in RLS-NDI at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Change From Baseline in RLS-NDI at Week 12-8.10 ± 2.88-4.30 ± 2.65-14.50 ± 2.50-6.60 ± 2.68
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Mixed Models Analysis · p = 0.7073 (This analysis was step 8 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -1.50 · 95% CI -9.30 to 6.30Spatial power covariance structure was used.
  • Pramipexole 0.25 mg vs Placebo · Mixed Models Analysis · p = 0.5299 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: 2.4 · 95% CI -5.1 to 9.9Spatial power covariance structure was used.
  • Pramipexole 0.5 mg vs Placebo · Mixed Models Analysis · p = 0.0354 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -7.9 · 95% CI -15.2 to -0.5Spatial power covariance structure was used.
SecondaryLimb Pain-Visual Analog Scale (Limb Pain-VAS)

100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

Time frame:
Baseline
Reported as:
Mean · mm
Limb Pain-Visual Analog Scale (Limb Pain-VAS)
mmPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Limb Pain-Visual Analog Scale (Limb Pain-VAS)4.20 ± 2.704.30 ± 2.584.00 ± 2.534.10 ± 2.52
SecondaryChange From Baseline in Limb Pain-VAS at Week 12

100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · mm
Change From Baseline in Limb Pain-VAS at Week 12
mmPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Change From Baseline in Limb Pain-VAS at Week 12-3.20 ± 0.20-2.64 ± 0.20-2.75 ± 0.21-2.20 ± 0.20
Statistical analysis
  • Pregabalin 300 mg vs Placebo · Mixed Models Analysis · p = 0.0004 (This analysis was step 9 in a step-down procedure (if p\<0.05, then continue to next step) used to control the Type I error rate. This procedure was stopped at Step 6. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -1.00 · 95% CI -1.55 to -0.45Spatial power covariance structure was used.
  • Pramipexole 0.25 mg vs Placebo · Mixed Models Analysis · p = 0.1242 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -0.43 · 95% CI -0.99 to 0.12Spatial power covariance structure was used.
  • Pramipexole 0.5 mg vs Placebo · Mixed Models Analysis · p = 0.0553 (This analysis was not included in the step-down procedure (if p\<0.05, then continue to next step) to control Type I error. The analysis was done at a significance level of alpha = 0.05, 2-sided.) · Ls mean difference: -0.55 · 95% CI -1.12 to 0.01Spatial power covariance structure was used.
SecondarySeverity of Augmentation Symptoms at Week 12

ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

Time frame:
Week 12
Reported as:
Mean · Units on a Scale
Severity of Augmentation Symptoms at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Severity of Augmentation Symptoms at Week 120.90 ± 1.601.60 ± 2.291.30 ± 1.871.40 ± 1.95
SecondaryClinical Global Impressions-Severity (CGI-S) at Week 12

CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.

Time frame:
Week 12
Reported as:
Mean · Units on a Scale
Clinical Global Impressions-Severity (CGI-S) at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Clinical Global Impressions-Severity (CGI-S) at Week 122.90 ± 1.183.50 ± 1.223.10 ± 1.173.70 ± 1.17
SecondaryMedical Outcomes Study-Sleep Scale (MOS-SS) at Week 12

MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.

Time frame:
Week 12
Reported as:
Mean · Units on a Scale
Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Sleep disturbance (n = 175, 169, 178, 171)30.50 ± 21.8439.30 ± 23.7234.40 ± 20.8938.60 ± 21.43
Snoring (n = 172, 169, 178, 170)29.00 ± 27.5025.80 ± 28.4625.80 ± 25.8124.60 ± 24.57
Awakening short of breath (n = 175, 169, 178, 171)10.50 ± 15.7812.30 ± 17.0913.80 ± 18.229.60 ± 15.13
Sleep adequacy (n = 128, 120, 133, 125 )61.30 ± 28.5754.80 ± 29.4555.20 ± 27.8750.00 ± 28.74
Somnolence (n = 175, 169, 178, 171)23.90 ± 17.5727.60 ± 18.6125.50 ± 18.6726.00 ± 18.77
Sleep quantity (n = 175, 169, 178, 171)6.80 ± 1.086.50 ± 1.256.60 ± 1.166.50 ± 1.26
Sleep problem index I (n = 175, 169, 178, 171)29.40 ± 17.2635.30 ± 18.8233.40 ± 16.7335.00 ± 16.54
Sleep problem index II (n = 175, 169, 178, 171)30.70 ± 17.1536.60 ± 18.9034.10 ± 17.0536.30 ± 16.81
SecondaryNumber of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12

MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12
ParticipantsPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 1284647768
SecondaryProfile of Mood State (POMS) at Week 12

POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryRestless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12

RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.

Time frame:
Week 12
Reported as:
Mean · Units on Scale
Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12
Units on ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 1277.75 ± 10.9273.33 ± 13.0275.48 ± 12.6973.23 ± 13.98
SecondaryMedical Outcomes Study-Short Form 36 (SF-36) at Week 12

SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.

Time frame:
Week 12
Reported as:
Mean · Units on a Scale
Medical Outcomes Study-Short Form 36 (SF-36) at Week 12
Units on a ScalePregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Physical functioning83.70 ± 18.3081.90 ± 19.5682.40 ± 19.9883.00 ± 19.22
Role physical81.20 ± 20.7579.60 ± 19.3779.10 ± 20.7181.50 ± 19.70
Bodily pain73.30 ± 20.5165.20 ± 20.1469.00 ± 20.4065.50 ± 20.03
General health73.60 ± 18.3769.80 ± 18.3370.50 ± 17.6872.80 ± 19.47
Vitality62.40 ± 19.2759.00 ± 19.6959.80 ± 20.1759.30 ± 20.51
Social functioning87.20 ± 18.0184.50 ± 18.1484.00 ± 18.7586.80 ± 18.37
Role emotional85.10 ± 18.9183.90 ± 17.7784.60 ± 18.0987.00 ± 18.25
Mental health77.40 ± 16.1374.60 ± 16.8076.10 ± 16.2978.70 ± 15.23
Summary physical score78.00 ± 16.5074.20 ± 15.9275.30 ± 16.4375.70 ± 16.03
Summary mental score78.00 ± 15.7375.50 ± 15.6076.10 ± 15.3278.00 ± 15.76
Summary of health status3.10 ± 0.473.10 ± 0.493.20 ± 0.543.10 ± 0.53
SecondaryWork Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12

WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.

Time frame:
Week 12
Reported as:
Mean · Percentage of impairment
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12
Percentage of impairmentPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo
Overall work (n= 10, 7, 11, 10)6.00 ± 9.665.70 ± 11.349.10 ± 20.7114.60 ± 23.39
Activity (n= 18, 22, 25, 20)12.20 ± 19.2720.90 ± 24.2822.80 ± 23.0123.00 ± 24.52
Work time missed (n= 10, 7, 11, 10)0.00 ± 0.000.00 ± 0.000.00 ± 0.001.50 ± 3.62

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 300 mg—9/182 (4.9%)134/182 (73.6%)
Pramipexole 0.25 mg—12/178 (6.7%)110/178 (61.8%)
Pramipexole 0.5 mg—9/180 (5%)118/180 (65.6%)
Placebo to Pregabalin 300 mg—5/59 (8.5%)42/59 (71.2%)
Placebo to Pramipexole 0.25 mg—2/59 (3.4%)34/59 (57.6%)
Placebo to Pramipexole 0.5 mg—0/61 (0%)41/61 (67.2%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo to Pregabalin 300 mgPlacebo to Pramipexole 0.25 mgPlacebo to Pramipexole 0.5 mg
Cholecystitis acuteHepatobiliary disorders0/1820/1780/1801/590/590/61
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1820/1781/1801/590/590/61
Cerebrovascular accidentNervous system disorders0/1821/1780/1801/590/590/61
Multiple sclerosisNervous system disorders0/1820/1780/1800/591/590/61
Suicidal ideationPsychiatric disorders0/1820/1780/1801/590/590/61
Withdrawal syndromePsychiatric disorders0/1820/1780/1801/590/590/61
Spinal deformity correctionSurgical and medical procedures0/1820/1780/1800/591/590/61
Chest painGeneral disorders0/1822/1780/1800/590/590/61
FallInjury, poisoning and procedural complications0/1821/1782/1800/590/590/61
Angina pectorisCardiac disorders0/1821/1780/1800/590/590/61
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo to Pregabalin 300 mgPlacebo to Pramipexole 0.25 mgPlacebo to Pramipexole 0.5 mg
DizzinessNervous system disorders39/18215/17817/18010/596/593/61
HeadacheNervous system disorders22/18230/17835/1809/596/5912/61
SomnolenceNervous system disorders32/18212/17814/1807/594/595/61
NasopharyngitisInfections and infestations19/18220/17817/1803/593/599/61
NauseaGastrointestinal disorders11/18218/17826/1803/593/594/61
InfluenzaInfections and infestations9/18213/1783/1804/598/597/61
FatigueGeneral disorders23/18219/17822/1807/595/598/61
Weight increasedInvestigations16/18212/17812/1802/597/594/61
ConstipationGastrointestinal disorders14/1823/1782/1805/591/590/61
DiarrhoeaGastrointestinal disorders7/1829/17810/1802/595/595/61

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo to Pregabalin 300 mgPlacebo to Pramipexole 0.25 mgPlacebo to Pramipexole 0.5 mgTotal
Less than 18 years0000000
18 to 44 years373445111720164
45 to 64 years1018584293231362
Greater than and equal to 65 years445951191010193
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 300 mgPramipexole 0.25 mgPramipexole 0.5 mgPlacebo to Pregabalin 300 mgPlacebo to Pramipexole 0.25 mgPlacebo to Pramipexole 0.5 mgTotal
Female12310899373638441
Male597081222323278
08

Study locations

110 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35209, United States
  • Pfizer Investigational Site
    Jasper, Alabama 35501, United States
  • Pfizer Investigational Site
    Tuscaloosa, Alabama 35406, United States
  • Pfizer Investigational Site
    Glendale, Arizona 85308, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85032, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85050, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72211, United States
  • Pfizer Investigational Site
    Northridge, California 91325, United States
  • Pfizer Investigational Site
    Redondo Beach, California 90277, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    San Diego, California 92121, United States
  • Pfizer Investigational Site
    Santa Monica, California 90404, United States
  • Pfizer Investigational Site
    Torrance, California 90502, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Boca Raton, Florida 33486, United States
  • Pfizer Investigational Site
    Hallandale Beach, Florida 33009, United States
  • Pfizer Investigational Site
    Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33026, United States
  • Pfizer Investigational Site
    South Miami, Florida 33143, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40217, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Pfizer Investigational Site
    Chevy Chase, Maryland 20815, United States
  • Pfizer Investigational Site
    Newton, Massachusetts 02459, United States
  • Pfizer Investigational Site
    Southfield, Michigan 48034, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55415, United States
  • Pfizer Investigational Site
    Princeton, New Jersey 08540, United States
  • Pfizer Investigational Site
    New York, New York 10019, United States
  • Pfizer Investigational Site
    Salisbury, North Carolina 28144-0000, United States
  • Pfizer Investigational Site
    Salisbury, North Carolina 28144, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45219, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Pfizer Investigational Site
    Lafayette Hill, Pennsylvania 19444, United States
  • Pfizer Investigational Site
    Austin, Texas 78731, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Houston, Texas 77063, United States
  • Pfizer Investigational Site
    Plano, Texas 75093, United States
  • Pfizer Investigational Site
    Walla Walla, Washington 99362, United States
  • Pfizer Investigational Site
    Innsbruck, A-6020, Austria
  • Pfizer Investigational Site
    Linz, A-4021, Austria
  • Pfizer Investigational Site
    Wien, 1090, Austria
  • Pfizer Investigational Site
    Helsinki, 00420, Finland
  • Pfizer Investigational Site
    Kuopio, 70210, Finland
  • Pfizer Investigational Site
    Tampere, 33520, Finland
  • Pfizer Investigational Site
    Turku, 20520, Finland
  • Pfizer Investigational Site
    Achim, 28832, Germany
  • Pfizer Investigational Site
    Bad Saarow, 15526, Germany
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Berlin, 10245, Germany
  • Pfizer Investigational Site
    Berlin, 10365, Germany
  • Pfizer Investigational Site
    Berlin, 10437, Germany
  • Pfizer Investigational Site
    Berlin, 10629, Germany
  • Pfizer Investigational Site
    Berlin, 10969, Germany
  • Pfizer Investigational Site
    Berlin, 12163, Germany
  • Pfizer Investigational Site
    Berlin, 12683, Germany
  • Pfizer Investigational Site
    Berlin, 13156, Germany
  • Pfizer Investigational Site
    Bochum, 44787, Germany
  • Pfizer Investigational Site
    Bochum, 44805, Germany
  • Pfizer Investigational Site
    Bremen, 28325, Germany
  • Pfizer Investigational Site
    Dortmund, 44229, Germany
  • Pfizer Investigational Site
    Dresden, 01307, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Gelsenkirchen, 45879, Germany
  • Pfizer Investigational Site
    Halle, 06118, Germany
  • Pfizer Investigational Site
    Hamm, 59065, Germany
  • Pfizer Investigational Site
    Jena, 07743, Germany
  • Pfizer Investigational Site
    Juelich, 52428, Germany
  • Pfizer Investigational Site
    Kassel, 34128, Germany
  • Pfizer Investigational Site
    Kassel, 34131, Germany
  • Pfizer Investigational Site
    Koethen, 06366, Germany
  • Pfizer Investigational Site
    Leipzig, 04107, Germany
  • Pfizer Investigational Site
    Marburg, 35039, Germany
  • Pfizer Investigational Site
    Muenchen, 80331, Germany
  • Pfizer Investigational Site
    Oldenburg, 26122, Germany
  • Pfizer Investigational Site
    Prien, 83209, Germany
  • Pfizer Investigational Site
    Schwerin, 19053, Germany
  • Pfizer Investigational Site
    Siegen, 57072, Germany
  • Pfizer Investigational Site
    Ulm, 89073, Germany
  • Pfizer Investigational Site
    Ulm, 89081, Germany
  • Pfizer Investigational Site
    Unterhaching, 82008, Germany
  • Pfizer Investigational Site
    Westerstede, 26655, Germany
  • Pfizer Investigational Site
    Wuerzburg, 97070, Germany
  • Pfizer Investigational Site
    Pavia, 27100, Italy
  • Pfizer Investigational Site
    Pisa, 56126, Italy
  • Pfizer Investigational Site
    Rome, 00163, Italy
  • Pfizer Investigational Site
    Rome, 00185, Italy
  • Pfizer Investigational Site
    Troina(EN), 94018, Italy
  • Pfizer Investigational Site
    Troina, 94018, Italy
  • Pfizer Investigational Site
    Ede, 6716 RP, Netherlands
  • Pfizer Investigational Site
    Zwolle, 8025 BV, Netherlands
  • Pfizer Investigational Site
    Barcelona, Cataluña/Spain 08003, Spain
  • Pfizer Investigational Site
    Barcelona, 08035, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    Granada, 18014, Spain
  • Pfizer Investigational Site
    Madrid, 28036, Spain
  • Pfizer Investigational Site
    Avesta, 77482, Sweden

Showing the first 100 of 110 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014 Feb 13;370(7):621-31. doi: 10.1056/NEJMoa1303646. PubMed 24521108 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 10, 2008
Start
Dec 2008
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Sep 27, 2012
Last update
Jan 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00806026
Responsible party
Sponsor
First posted
Dec 10, 2008
Start date
Dec 2008
Primary completion
May 2011
Completion
May 2011
Results posted
Sep 27, 2012
Last update
Jan 26, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion